BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Acella Pharmaceuticals, LLC Announces Approval And Launch Of Loutrex Topical Cream


1/31/2014 7:16:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Acella Pharmaceuticals, LLC, Announces Approval and Launch of Loutrex Topical Cream

ATLANTA, Jan. 31, 2014 /PRNewswire/ -- Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, recently announced the approval and launch of Loutrex Topical Cream following a successful 510(k)1 notification with the Food and Drug Administration (FDA), which determined that Acella's 510(k) submission was equivalent to another legally U.S.-marketed device and at least as safe and effective as the predicate.

The approved 510(k) (Loutrex) is indicated to manage and relieve the signs and symptoms of seborrhea and seborrheic dermatitis such as itching, erythema, scaling and pain. The product helps relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

"I would like to thank Acella's Research and Development Team and Akesis, LLC (Lake Wylie, SC) for their work with the FDA to help get Loutrex to our customers," stated Allen Fields, Vice President, Head of Research and Development for Acella Pharmaceuticals.

About Acella Pharmaceuticals, LLC

Acella develops markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients. For additional information please contact Acella at 678-325-5189.

1. Section 510(k) of the Food, Drug and Cosmetic Act requires device manufacturers who must register, to notify FDA of their intent to market a medical device at least 90 days in advance. This is known as Premarket Notification - also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories. (Source: http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/510kclearances/default.htm)

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES